Description
BPC-157 & TB-500 Peptide Blend
BPC-157 Peptide, also known as Pentadecapeptide BPC-157, or Body Protection Compound 157, originated from a protein found in the digestive system, and has been suggested in various studies to potentially help with healing joint, tendon, and muscle tissue, as well as nerve tissue.
TB-500 Peptide, also known as Thymosin beta-4, or TB-4, has been suggested by researchers to possibly assist in the healing process after injury, especially brain and neurological injury. Other TB-500 research has suggested it helps with wound healing and with hair growth.
Both BPC-157 and TB-500 are synthetic polypeptides, where TB-500 is composed of 43 amino acids (1) and BPC-157 is composed of 15 amino acids (2).
TB-500 peptide is the synthetic form of Thymosin beta 4, a naturally occurring protein that is considered to induce angiogenesis and may elevate the wound healing process (3). Likewise, BPC-157 peptide is the synthetic form of the protein segment derived from gastric juice (4). Resembling the naturally occurring proteins in structure, this suggests both peptides may be stable and biocompatible.
Overview
TB-500 has been suggested to exert potential action via elevating the levels of actin proteins. TB-500 has a distinct amino acid segment [(17)LKKTETQ(23)] which is hypothesized to be responsible for actin binding and potentially enhancing wound healing processes (8).
BPC-157 peptide has been suggested to exert some action via stimulating growth hormone receptors. The peptide appears to bind with receptors and may induce cell proliferation. As a result, new tissues composed of collagen may be formed, thereby possibly enhancing the healing of wounds more rapidly (4).
As both TB-500 and BPC-157 peptides demonstrate similar pharmacological potential, when blended together, it may maximize the potential action of both – what would otherwise occur with one peptide, might occur at a better, faster rate when combined. Studies conducted in BPC-157 & TB-500 peptides suggest that the peptides may individually exhibit some potential for the following possible mechanisms of action:
- Possibly elevate angiogenesis – faster wound healing
- Possibly stimulate tendon, muscle, bone, and ligament healing
- Possibly reduce inflammation
- Possibly decrease pain levels
- Possibly induce tissue repair
Research and Clinical Studies
There are no research or clinical studies currently available where both TB-500 and BPC-157 were used in the same experiment or presented in combination in the same test model. However, below listed are the studies observing the potential action of the individual peptides.
TB-500 Peptide and Tissue Repair
In this 1999 study (9) the experimentally wounded rats were used as subjects, where half the number of rats were presented with saline and the rest were presented with TB-500 peptide. The main aim of this study was to determine the potential tissue repair action of the peptide. Four days after the experiment, it was reported by the researchers that the rats presented with TB-500 showed an apparent 41% increment in the re-epithelialization process (i.e., formation of new epithelial cells to resurface the wound). After seven days, the wounds presented with TB-500 had reportedly contracted by at least 11% as compared to the saline wounds.
In this 2006 clinical trial (10), 72 test subjects with pressure ulcers were presented with TB-500. The main aim of this randomized, double blind study was to establish the potential of thymosin beta 4 (analogous to TB-500) in ulcer presence. The test subjects were divided into two groups, where one group was presented with placebo for 84 days and the rest were presented with various concentrations of the peptide, daily for up to 84 days. After 84 days, there was an occurrence of wound healing process where the ulcers reportedly exhibited signs of healing.
TB-500 Peptide and Ligaments
In this study (11), the medial collateral ligament (MCL) of the rats was transected (cut across) during surgery. All the rats were then presented with a fibrin sealing agent, where some rats were also presented with thymosin beta 4 (TB-500). Four weeks after the surgery, it was reported by the researchers that the healing tissues in the peptide rats exhibited apparently evenly formed and spaced collagen cells. The collagen cells formed in the peptide rats were reportedly wider as compared to the control rats.
BPC-157 Peptide and Tissue Repair
In this study (12), three experimental models of rats were used as subjects where all were experimentally wounded, either acute or chronic wounds. These rats were then divided into two groups, where one was presented with placebo and the other was presented with BC-157 peptide. After the experiment, all the rats were histologically examined, and it was determined that the rats with BPC-157 had a prominently higher number of collagen and blood vessels formed as compared to the placebo rats.
BPC-157 Peptide and Muscle
This study (13) was conducted on rats with experimentally injured gastrocnemius muscle complex. These rats were initially presented with corticosteroids, which reportedly contributed to severe muscular damage in these rats. These rats were then divided into two groups, where one was presented with placebo and the other with BPC-157 daily for up to 14 days. After the experiment, it was reported that the BPC-157 rats appeared to exhibit complete restoration of their gastric muscles along with full ability to function. Whereas, the placebo treated group did not exhibit any apparent significant change to the damaged muscles.
BPC-157 & TB-500 Peptide Blend is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.
References:
1. National Center for Biotechnology Information. “PubChem Compound Summary for CID 132558700, CID 132558700” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/132558700
2. National Center for Biotechnology Information. “PubChem Compound Summary for CID 9941957” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Bpc-157
3. Ho EN, Kwok WH, Lau MY, Wong AS, Wan TS, Lam KK, Schiff PJ, Stewart BD. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012 Nov 23. https://pubmed.ncbi.nlm.nih.gov/23084823/
4. Chang, Chung-Hsun et al. “The promoting effect of pentadecapeptide BPC-157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” Journal of applied physiology (Bethesda, Md. : 1985) vol. 110,3 (2011): 774-80. doi:10.1152/japplphysiol.00945.2010. https://pubmed.ncbi.nlm.nih.gov/21030672/
5. Sikiric, Predrag et al. “Brain-gut Axis and Pentadecapeptide BPC-157: Theoretical and Practical Implications.” Current neuropharmacology vol. 14,8 (2016): 857-865. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333585/#r1
6. Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC-157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol. 2009 Dec;60 Suppl 7:191-6 https://pubmed.ncbi.nlm.nih.gov/20388964/
7. Julia Parmley, A Life-Saving Discovery, January 04, 2010. gwhtoday.gwu.edu/life-saving-discovery
8. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008 May 15;453(7193):314-21. doi: 10.1038/nature07039. PMID: 18480812. https://pubmed.ncbi.nlm.nih.gov/18480812/
9. Katherine M. Malinda et.al, Thymosin β4 Accelerates Wound Healing, Journal of Investigative Dermatology, Volume 113, Issue 3, 1999, Pages 364-368, ISSN 0022-202X, https://www.sciencedirect.com/science/article/pii/S0022202X15405950
10. Study of Thymosin Beta 4 in Patients With Pressure Ulcers. https://www.clinicaltrials.gov/ct2/show/NCT00382174
11. Xu B, Yang M, Li Z, Zhang Y, Jiang Z, Guan S, Jiang D. Thymosin β4 enhances the healing of medial collateral ligament injury in rat. Regul Pept. 2013 Jun 10;184:1-5. doi: 10.1016/j.regpep.2013.03.026. https://pubmed.ncbi.nlm.nih.gov/23523891/
12. S Seiwerth, et al. “BPC-157’s effect on healing.” Journal of physiology, Paris vol. 91,3-5 (1997): 173-8. doi:10.1016/s0928-4257(97)89480-6. https://pubmed.ncbi.nlm.nih.gov/9403790/
13. Pevec D, Novinscak T, Brcic L, Sipos K, Jukic I, Staresinic M, Mise S, Brcic I, Kolenc D, Klicek R, Banic T, Sever M, Kocijan A, Berkopic L, Radic B, Buljat G, Anic T, Zoricic I, Bojanic I, Seiwerth S, Sikiric P. Impact of pentadecapeptide BPC-157 on muscle healing impaired by systemic corticosteroid application. Med Sci Monit. 2010 Mar;16(3):BR81-88. PMID: 20190676. https://pubmed.ncbi.nlm.nih.gov/20190676/
14. List of prohibited items (WADA) https://www.wada-ama.org/en/
NOTE: These products are intended for laboratory research use only. BPC-157 & TB-500 stack (10mg) is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.
Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
